Centiva Capital’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $373K | Buy |
2,953
+1,301
| +79% | +$171K | ﹤0.01% | 1060 |
|
|
2026
Q1 | $230K | Sell |
1,652
-109
| -6% | -$15.3K | ﹤0.01% | 1204 |
|
|
2025
Q4 | $216K | Buy |
+1,761
| New | +$214K | ﹤0.01% | 971 |
|
|
2025
Q2 | – | Sell |
-5,877
| Closed | -$659K | – | 1746 |
|
|
2025
Q1 | $659K | Buy |
5,877
+4,581
| +353% | +$473K | 0.02% | 681 |
|
|
2024
Q4 | $120K | Sell |
1,296
-16,315
| -93% | -$1.47M | ﹤0.01% | 1472 |
|
|
2024
Q3 | $1.48M | Buy |
17,611
+16,884
| +2,322% | +$1.29M | 0.03% | 613 |
|
|
2024
Q2 | $49.9K | Sell |
727
-5,252
| -88% | -$350K | ﹤0.01% | 1925 |
|
|
2024
Q1 | $438K | Buy |
5,979
+4,034
| +207% | +$310K | 0.01% | 1056 |
|
|
2023
Q4 | $158K | Sell |
1,945
-2,054
| -51% | -$160K | ﹤0.01% | 1493 |
|
|
2023
Q3 | $300K | Buy |
3,999
+3,375
| +541% | +$260K | 0.01% | 1178 |
|
|
2023
Q2 | $48.1K | Sell |
624
-71,776
| -99% | -$5.72M | ﹤0.01% | 1506 |
|
|
2023
Q1 | $6.01M | Buy |
72,400
+34,579
| +91% | +$2.86M | 0.15% | 146 |
|
|
2022
Q4 | $3.25M | Buy |
37,821
+33,463
| +768% | +$2.65M | 0.09% | 225 |
|
|
2022
Q3 | $269K | Buy |
+4,358
| New | +$275K | 0.01% | 1086 |
|
|
2022
Q2 | – | Sell |
-27,057
| Closed | -$1.68M | – | 1792 |
|
|
2022
Q1 | $1.61M | Buy |
+27,057
| New | +$1.73M | 0.03% | 509 |
|
|
2021
Q4 | – | Sell |
-7,510
| Closed | -$517K | – | 1333 |
|
|
2021
Q3 | $525K | Buy |
+7,510
| New | +$528K | 0.03% | 595 |
|
|
2021
Q2 | – | Sell |
-10,190
| Closed | -$680K | – | 1467 |
|
|
2021
Q1 | $659K | Sell |
10,190
-6,971
| -41% | -$449K | 0.03% | 468 |
|
|
2020
Q4 | $1M | Buy |
17,161
+8,830
| +106% | +$533K | 0.04% | 274 |
|
|
2020
Q3 | $526K | Buy |
8,331
+937
| +13% | +$65K | 0.03% | 320 |
|
|
2020
Q2 | $569K | Buy |
+7,394
| New | +$567K | 0.03% | 261 |
|
|
2020
Q1 | – | Sell |
-22,870
| Closed | -$1.58M | – | 728 |
|
|
2019
Q4 | $1.49M | Buy |
22,870
+2,448
| +12% | +$159K | 0.07% | 239 |
|
|
2019
Q3 | $1.29M | Buy |
20,422
+4,411
| +28% | +$288K | 0.08% | 195 |
|
|
2019
Q2 | $1.08M | Buy |
16,011
+10,924
| +215% | +$719K | 0.06% | 201 |
|
|
2019
Q1 | $331K | Sell |
5,087
-40,493
| -89% | -$2.69M | 0.02% | 251 |
|
|
2018
Q4 | $2.85M | Buy |
45,580
+15,835
| +53% | +$1.11M | 0.23% | 61 |
|
|
2018
Q3 | $2.3M | Buy |
+29,745
| New | +$2.25M | 0.2% | 75 |
|
|
2018
Q2 | – | Sell |
-300
| Closed | -$21.2K | – | 115 |
|
|
2018
Q1 | $23K | Buy |
+300
| New | +$23.8K | 0.01% | 52 |
|
Other funds holding GILD
Centiva Capital's GILD Position: Q2 2026 in Review
Centiva Capital increased its Gilead Sciences (GILD) stake by 79% in Q2 2026, buying an estimated $171K and bringing the position to 2,953 shares worth $373K. The position accounts for ﹤0.01% of the portfolio, ranked #1060.
Centiva Capital first reported a position in GILD in Q1 2018 and has held it in 27 quarters since. The position peaked at $6.01M in Q1 2023. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Centiva Capital held 2,953 shares of Gilead Sciences worth $373K as of Q2 2026.
- Centiva Capital bought 1,301 Gilead Sciences shares in Q2 2026, an estimated $171K.
- Gilead Sciences made up ﹤0.01% of Centiva Capital's portfolio in Q2 2026, its #1060 holding.
- Centiva Capital first reported a position in Gilead Sciences in Q1 2018 and has held it in 27 quarters since.
- Centiva Capital's Gilead Sciences position peaked at $6.01M in Q1 2023.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.